They suggested that targeting eotaxin/CCL11 with monoclonal antibodies could reduce cardiac mast cell infiltration, possibly resulting in decreased myocardial fibrosis and improved contractile function after heart transplantation [34]. The gene discussed is CCL11; the disease is Myocardial fibrosis.